ATOS – atossa therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
Atossa Genetics (NASDAQ:ATOS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 [Yahoo! Finance]
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
Form 8-K ATOSSA THERAPEUTICS, For: Feb 19
Form 424B5 ATOSSA THERAPEUTICS,
Form 424B3 ATOSSA THERAPEUTICS,
Form 8-K ATOSSA THERAPEUTICS, For: Feb 17
Form 8-K ATOSSA THERAPEUTICS, For: Feb 11
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.